Différences entre versions de « Syndrome de lyse tumorale »
De médecine.top
(Page créée avec « == Caractéristiques == hyperuricemia, hyperkalemia, hyperphosphatemia, and hypocalcemia. These electrolyte abnormalities can lead to acute kidney injury, cardiac arrhythm... ») |
|||
| Ligne 1 : | Ligne 1 : | ||
== Caractéristiques == | == Caractéristiques == | ||
hyperuricemia, hyperkalemia, hyperphosphatemia, and hypocalcemia. These electrolyte abnormalities can lead to acute kidney injury, cardiac arrhythmias, seizures, and death. | hyperuricemia, hyperkalemia, hyperphosphatemia, and hypocalcemia. These electrolyte abnormalities can lead to acute kidney injury, cardiac arrhythmias, seizures, and death. | ||
| + | |||
| + | == Surveillance == | ||
| + | * Monitoring cardiaque en continu | ||
== Traitement == | == Traitement == | ||
| − | Patients at intermediate risk for TLS can be managed with monitoring of laboratory values, hydration, and allopurinol, and those at high risk should receive intravenous hydration and rasburicase, a urate oxidase enzyme that metabolizes uric acid, before receiving chemotherapy | + | Patients at intermediate risk for TLS can be managed with monitoring of laboratory values, hydration, and allopurinol, and those at high risk should receive intravenous hydration and rasburicase, a urate oxidase enzyme that metabolizes uric acid, before receiving chemotherapy |
| + | * Hydratation aggressive | ||
| + | * Diurétique de l'anse | ||
| + | * +/- hémofiltration | ||
| + | == Suivi == | ||
| + | * Acide urique aux 4-6 heures | ||
[[Category:Oncologie]] | [[Category:Oncologie]] | ||
Version actuelle datée du 18 juin 2020 à 11:42
Caractéristiques
hyperuricemia, hyperkalemia, hyperphosphatemia, and hypocalcemia. These electrolyte abnormalities can lead to acute kidney injury, cardiac arrhythmias, seizures, and death.
Surveillance
- Monitoring cardiaque en continu
Traitement
Patients at intermediate risk for TLS can be managed with monitoring of laboratory values, hydration, and allopurinol, and those at high risk should receive intravenous hydration and rasburicase, a urate oxidase enzyme that metabolizes uric acid, before receiving chemotherapy
- Hydratation aggressive
- Diurétique de l'anse
- +/- hémofiltration
Suivi
- Acide urique aux 4-6 heures
